ReviewDrugs2024
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
Review in Drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes.Frontiers in endocrinology · 2025Pooled it
- Polymer-based Vaginal Insert Systems: Engineering Controlled Drug Delivery for Women's Health.AAPS PharmSciTech · 2026Review
- Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Contemporary Management of Uterine Fibroids.Journal of clinical medicine · 2026Review
- Piezo1 mediates hypoxia-induced endometriosis fibrosis via the mtDNA -dependent cGAS-STING pathway.Journal of translational medicine · 2026Article
- Comparative post-marketing reporting signals of elagolix and myfembree in endometriosis: a FAERS pharmacovigilance study.Frontiers in pharmacology · 2026Article
- Combined pelvic floor training and hormonal therapy for endometriosis pain recurrence: a propensity score-matched study.Frontiers in medicine · 2026Article
- Review
- Changes in Periprosthetic Bone Mineral Density Following Arthroplasty: An In-Depth Review and Current Perspectives.Current osteoporosis reports · 2025Review
- The Novel Imipramine-Magnesium Complex Exerts Antidepressant-like Activity in Mice Subjected to the Forced Swim Test and the Tail Suspension Test.Molecules (Basel, Switzerland) · 2025Article
- Efficacy and safety of traditional Chinese medicine for endometriosis-related pain: a meta-analysis.American journal of translational research · 2025Review
- Endometriosis and Mortality Risk in US Women: Findings From NHANES 1999-2006.International journal of women's health · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.